Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of D745 (Empagliflozin) Added to Metformin and Sitagliptin in T2DM
NCT05566028Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Change from baseline in Hemoglobin A1c at 24 weeks. Started Oct 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05566028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566028.